Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 18/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 0.72 |
| ▸ | ATM | Q13315 | 1/20 | 0.72 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.60 |
| ▸ | CDK2 | P24941 | 1/20 | 0.60 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.60 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977244 | 0.90 | ATR (0.81) | ATRPRKDCATM | |
| SCHEMBL3054972 | 0.89 | ATR (1.00) | ATRPRKDCATM | |
| SCHEMBL13138778 | 0.88 | ATR (0.78) | ATRPRKDCATM | |
| SCHEMBL4009915 | 0.87 | ATR (0.77) | ATRPRKDCATMEGFR | |
| SCHEMBL2513432 | 0.86 | ATR (1.00) | ATRPRKDCATM | |
| SCHEMBL2509897 | 0.86 | ATR (1.00) | ATRPRKDCATMPDPK1CDK1 | |
| SCHEMBL3979058 | 0.86 | ATR (0.76) | ATRPRKDCATMPDPK1CDK1 | |
| SCHEMBL3469604 | 0.86 | ATR (0.76) | ATRPRKDCATMPDPK1CDK1 | |
| SCHEMBL4006257 | 0.86 | ATR (0.74) | ATRPRKDCATMCDK1CDK2 | |
| SCHEMBL13138782 | 0.85 | ATR (0.77) | ATRPRKDCATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| EP-4059932-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-4059932-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-3354650-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3354650-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11179394-B2 | Method for treating cancer using a combination of Chk1 and ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-11-23 | — | — | US | disclosed |
| US-11110086-B2 | Compounds useful as inhibitors of ATR kinase and combination therapies thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-09-07 | — | — | US | disclosed |
| US-10961232-B2 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-03-30 | — | — | US | disclosed |
| US-10961232-B2 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-03-30 | — | — | US | disclosed |
| US-20150031661-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-29 | — | — | US | disclosed |
| US-8841308-B2 | Pyrazin-2-amines useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841308-B2 | Pyrazin-2-amines useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841308-B2 | Pyrazin-2-amines useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140044802-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-13 | — | — | US | disclosed |
| EP-2376485-A1 | PYRAZINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2010071837-A1 | PYRAZINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11110086-B2 | Compounds useful as inhibitors of ATR kinase and combination therapies thereof | ATR, CHEK1, CHEK2 | ATR 1/4885PRKDC 20/4885ATM 16/4885 |
| US-10961232-B2 | Substituted pyrazines as ATR kinase inhibitors | ATR, MAP3K5, CHEK1 | ATR 1/4885PRKDC 29/4885ATM 41/4885 |
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885PRKDC 23/4885ATM 39/4885 |
| US-11179394-B2 | Method for treating cancer using a combination of Chk1 and ATR inhibitors | CHEK1, CHEK2, ATR | ATR 3/4885PRKDC 73/4885ATM 7/4885 |
| US-20150031661-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885PRKDC 23/4885ATM 39/4885 |
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885PRKDC 23/4885ATM 39/4885 |
| US-20140044802-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF | ATR, CHEK1, CHEK2 | ATR 1/4885PRKDC 20/4885ATM 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.